RUNX1 and acute myeloid leukemia: The concurrence of FLT3-ITD mutation is an adverse prognostic finding in CEBPA mutated-AML patients (23). RUNX1 encodes the DNA binding alpha subunit of the core binding factor (CBFalpha) that is involved in the normal differentiation of hematopoietic cells.